RESUMO
Obinutuzumab frequently triggers an infusion reaction(IR). In the GALLIUM study, despite the use of corticosteroids, antipyretic analgesics, and antihistamines to prevent IR, IR occurred at a high frequency of 68.2% for all Grades and 12.4% for Grades 3 or higher. The dose of methylprednisolone was increased from 80 mg administered in the GALLIUM study to 125 mg, and the development of IR was investigated in 30 patients with follicular lymphoma who received the initial dose of obinutuzumab. The incidence of IR was 43.3% for all Grades and 0% for Grades 3 or higher, and no serious IR was observed. It also had no effect on infectious diseases. Increased doses of corticosteroids were well tolerated and suggested as an effective method for reducing the frequency of IR.
Assuntos
Gálio , Linfoma Folicular , Humanos , Anticorpos Monoclonais Humanizados , Corticosteroides/uso terapêutico , Linfoma Folicular/tratamento farmacológico , Linfoma Folicular/induzido quimicamente , Linfoma Folicular/patologia , Pré-Medicação , Gálio/uso terapêuticoRESUMO
Materials imbued with uniformly dispersed, photo-responsive nanoparticles are instrumental in sustainable energy and photonic applications. Conventional methods, however, constrain their all-solar response. An innovative alternative is proposed: submerged photo-synthesis of crystallites (SPsC). It is shown that strategic doping with copper and oxygen vacancies can induce opto-critical phases from the nonstoichiometric tungstic acids (WO3 ·H2 O). These opto-critical phases enable a dynamic equilibrium shift in lattice defect stabilization, facilitating an unprecedented a whole solar wavelength response. This response manifests as photothermal, photo-assisted water evaporation, and photo-electrochemical characteristics. Harnessing all-solar energy, this one-pot SPsC strategy may steer the design and development of advanced oxide materials, enhancing functionality across diverse application domains.